メインナビゲーションにスキップ 検索にスキップ メインコンテンツにスキップ

UGT1A1 polymorphism as a prognostic indicator of stage I ovarian clear cell carcinoma patients treated with irinotecan

  • Tomoko Yoshihama
  • , Akira Hirasawa
  • , Hiroyuki Nomura
  • , Tomoko Akahane
  • , Yoshiko Nanki
  • , Wataru Yamagami
  • , Fumio Kataoka
  • , Eiichiro Tominaga
  • , Nobuyuki Susumu
  • , Taisei Mushiroda
  • , Daisuke Aoki

研究成果: ジャーナルへの寄稿 › 学術論文 › 査読

5   !!Link opens in a new tab 被引用数 (Scopus)

抄録

We investigated whether UGT1A1 polymorphisms are associated with the prognosis of ovarian cancer patients treated with irinotecan. UGT1A1 genotypes were analyzed in 11 stage I ovarian clear cell carcinoma patients who received irinotecan as first-line therapy. Progression-free survival, overall survival and adverse events were also assessed for each genotype. Three patients harbored UGT1A1*1/*6 while another three harbored UGT1A1*1/*28. Two patients with a wildtype genotype experienced recurrence and one died, whereas no recurrence or death was observed in patients with heterozygous genotypes. Adverse events tended to be more severe in patients with UGT1A1*6 and *28, although progression-free survival and overall survival rates tended to be better than in wild-type; the differences were not significant. We conclude that UGT1A1 polymorphisms have the potential to be a prognostic marker of irinotecan treatment.

本文言語英語
ページ(範囲)170-174
ページ数5
ジャーナルJapanese journal of clinical oncology
巻47
号2
DOI
出版ステータス出版済み - 01-02-2017
外部発表はい

UN SDG

この成果は、次の持続可能な開発目標に貢献しています

  1. SDG 3 - すべての人に健康と福祉を
    SDG 3 すべての人に健康と福祉を

All Science Journal Classification (ASJC) codes

  • 腫瘍学
  • 放射線学、核医学およびイメージング
  • 癌研究

フィンガープリント

「UGT1A1 polymorphism as a prognostic indicator of stage I ovarian clear cell carcinoma patients treated with irinotecan」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。

引用スタイル